Highlights
About
Whole-genome Cancer Treatment Intelligence Platform
C2i Genomics empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection. Its SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using scientific breakthroughs, growing genomic and clinical databases, and sophisticated signal processing and artificial intelligence, C2i enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development.
C2i Genomics provides acuity in cancer detection and monitoring by combining whole genome sequencing with a proprietary AI-based tumor enrichment method that recognizes patient-specific cancer patterns.
Identity
| Name | C2i Genomics |
|---|---|
| Slug | c2i-genomics |
| Type / kind | startup |
| Crunchbase ID | c2i-genomics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4MbmpccLDA |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by Veracyte on Jan, 2024 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Tirat Carmel |
| HQ address | Nahum Het Street 5, Haifa, Israel |
Web & social
| Website | https://www.veracyte.com/mrd-technology |
|---|---|
| Careers page | https://c2i-genomics.com/careers |
| https://www.linkedin.com/company/36105135 | |
| Twitter / X | https://twitter.com/C2iGenomics |
Classifications
Funding
| Total raised | $113.2M |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}